Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18213708 | 0.90 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2CAR | |
| SCHEMBL396834 | 0.90 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2CAR | |
| SCHEMBL12827168 | 0.82 | PNMT (0.43) | PNMTADRA2AADRA2BADRA2CAR | |
| SCHEMBL257552 | 0.80 | ALDH1A1 (0.62) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL28239780 | 0.80 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL6968655 | 0.80 | ALDH1A1 (0.62) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL13222445 | 0.75 | PGR (0.40) | PNMTADRA2AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13062867 | 0.75 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL27897828 | 0.75 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL17656378 | 0.74 | HTR5A (0.36) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| EP-1181288-B1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | UPJOHN CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN | 2002-10-03 | — | — | US | disclosed |
| US-6387896-B1 | GRAMNEGATIVE, GRAMPOSITVE BACTERIA | PHARMACIA & UPJOHN CO. | 2002-05-14 | — | — | US | disclosed |
| EP-1181288-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073301-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | OXA1L, MRPL21, RPS4Y1 | PNMT 4853/4885ADRA2A 4067/4885ADRA2B 3754/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | PNMT 4032/4885ADRA2A 673/4885ADRA2B 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.